{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:24:30Z","timestamp":1777587870964,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T00:00:00Z","timestamp":1485302400000},"content-version":"vor","delay-in-days":390,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1038\/mtna.2016.49","type":"journal-article","created":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T11:24:14Z","timestamp":1468927454000},"page":"e338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["CNS-restricted Transduction and CRISPR\/Cas9-mediated Gene Deletion with an Engineered AAV Vector"],"prefix":"10.1016","volume":"5","author":[{"given":"Giridhar","family":"Murlidharan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lavanya","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis","family":"Corriher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aravind","family":"Asokan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/mtna.2016.49_bib1","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/mt.2013.226","article-title":"Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy","volume":"21","author":"Flotte","year":"2013","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2016.49_bib2","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1038\/mtna.2016.49_bib3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/jamaneurol.2015.1807","article-title":"Nerve growth factor gene therapy: activation of neuronal responses in Alzheimer disease","volume":"72","author":"Tuszynski","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1038\/mtna.2016.49_bib4","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1412965","article-title":"Improvement and decline in vision with gene therapy in childhood blindness","volume":"372","author":"Jacobson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1038\/mtna.2016.49_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1038\/mtna.2016.49_bib6","doi-asserted-by":"crossref","first-page":"20139","DOI":"10.1038\/mtm.2013.9","article-title":"Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side-effects","volume":"1","author":"Gao","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1038\/mtna.2016.49_bib7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nbt.3471","article-title":"Therapeutic genome editing by combined viral and nonviral delivery of CRISPR system components in vivo","volume":"34","author":"Yin","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mtna.2016.49_bib8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nbt.3055","article-title":"In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9","volume":"33","author":"Swiech","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mtna.2016.49_bib9","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","article-title":"CRISPR-Cas9 knockin mice for genome editing and cancer modeling","volume":"159","author":"Platt","year":"2014","journal-title":"Cell"},{"key":"10.1038\/mtna.2016.49_bib10","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"10.1038\/mtna.2016.49_bib11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"},{"key":"10.1038\/mtna.2016.49_bib12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"key":"10.1038\/mtna.2016.49_bib13","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1073\/pnas.0937739100","article-title":"Adeno-associated viruses undergo substantial evolution in primates during natural infections","volume":"100","author":"Gao","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mtna.2016.49_bib14","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","article-title":"Clades of adeno-associated viruses are widely disseminated in human tissues","volume":"78","author":"Gao","year":"2004","journal-title":"J Virol"},{"key":"10.1038\/mtna.2016.49_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1089\/hum.2015.025","article-title":"Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success\u2013a personal perspective","volume":"26","author":"Hastie","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtna.2016.49_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/1073858414521870","article-title":"Adeno-associated virus vectors and neurological gene therapy","volume":"21","author":"Ojala","year":"2015","journal-title":"Neuroscientist"},{"key":"10.1038\/mtna.2016.49_bib17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/mt.2013.281","article-title":"Parkinson's disease gene therapy: success by design meets failure by efficacy","volume":"22","author":"Bartus","year":"2014","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2016.49_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mtna.2016.49_bib19","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/mt.2011.72","article-title":"Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates","volume":"19","author":"Gray","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2016.49_bib20","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/mt.2011.157","article-title":"Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders","volume":"19","author":"Bevan","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2016.49_bib21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/hum.2011.200","article-title":"Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates","volume":"23","author":"Samaranch","year":"2012","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtna.2016.49_bib22","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/mt.2014.68","article-title":"Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10","volume":"22","author":"Yang","year":"2014","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2016.49_bib23","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/mt.2010.279","article-title":"MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression","volume":"19","author":"Xie","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2016.49_bib24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1089\/humc.2013.239","article-title":"Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase: a cDNA to nonhuman primates","volume":"25","author":"Rosenberg","year":"2014","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1038\/mtna.2016.49_bib25","doi-asserted-by":"crossref","first-page":"13532","DOI":"10.1074\/jbc.M110.210922","article-title":"Terminal N-linked galactose is the primary receptor for adeno-associated virus 9","volume":"286","author":"Shen","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1038\/mtna.2016.49_bib26","doi-asserted-by":"crossref","first-page":"28814","DOI":"10.1074\/jbc.M113.482380","article-title":"Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency","volume":"288","author":"Shen","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1038\/mtna.2016.49_bib27","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1073\/pnas.97.7.3428","article-title":"Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system","volume":"97","author":"Davidson","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mtna.2016.49_bib28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ymthe.2004.05.024","article-title":"Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system","volume":"10","author":"Burger","year":"2004","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2016.49_bib29","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1128\/JVI.72.2.1438-1445.1998","article-title":"Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions","volume":"72","author":"Summerford","year":"1998","journal-title":"J Virol"},{"key":"10.1038\/mtna.2016.49_bib30","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1097\/00001756-200107030-00037","article-title":"Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain","volume":"12","author":"Nguyen","year":"2001","journal-title":"Neuroreport"},{"key":"10.1038\/mtna.2016.49_bib31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1006\/mthe.2002.0564","article-title":"Recombinant adeno-associated virus serotypes 2- and 5-mediated gene transfer in the mammalian brain: quantitative analysis of heparin co-infusion","volume":"5","author":"Mastakov","year":"2002","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2016.49_bib32","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/mt.2011.3","article-title":"A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction","volume":"19","author":"Kotchey","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2016.49_bib33","doi-asserted-by":"crossref","first-page":"10408","DOI":"10.1128\/JVI.01155-12","article-title":"Glycan binding avidity determines the systemic fate of adeno-associated virus type 9","volume":"86","author":"Shen","year":"2012","journal-title":"J Virol"},{"key":"10.1038\/mtna.2016.49_bib34","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/ng.940","article-title":"Genome-wide association study identifies five new schizophrenia loci","volume":"43","author":"Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium","year":"2011","journal-title":"Nat. Genet"},{"key":"10.1038\/mtna.2016.49_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/mp.2011.170","article-title":"Validation of schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 as miR-137 targets","volume":"18","author":"Kwon","year":"2013","journal-title":"Mol Psychiatry"},{"key":"10.1038\/mtna.2016.49_bib36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lfs.2014.04.024","article-title":"Post-transcriptional regulation by miR-137 underlies the low abundance of CAR and low rate of bilirubin clearance in neonatal mice","volume":"107","author":"Chen","year":"2014","journal-title":"Life Sci"},{"key":"10.1038\/mtna.2016.49_bib37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fnmol.2014.00076","article-title":"Biology of adeno-associated viral vectors in the central nervous system","volume":"7","author":"Murlidharan","year":"2014","journal-title":"Front Mol Neurosci"},{"key":"10.1038\/mtna.2016.49_bib38","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1172\/JCI57367","article-title":"The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice","volume":"121","author":"Bell","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1038\/mtna.2016.49_bib39","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1523\/JNEUROSCI.19-17-07415.1999","article-title":"Regulated expression and subcellular localization of syndecan heparan sulfate proteoglycans and the syndecan-binding protein CASK\/LIN-2 during rat brain development","volume":"19","author":"Hsueh","year":"1999","journal-title":"J Neurosci"},{"key":"10.1038\/mtna.2016.49_bib40","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1523\/JNEUROSCI.2185-07.2007","article-title":"A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease","volume":"27","author":"Cearley","year":"2007","journal-title":"J Neurosci"},{"key":"10.1038\/mtna.2016.49_bib41","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0169-409X(03)00101-7","article-title":"Spinal delivery of analgesics in experimental models of pain and analgesia","volume":"55","author":"Fairbanks","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1038\/mtna.2016.49_bib42","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1038\/mtna.2014.64","article-title":"COSMID: A Web-based tool for identifying and validating CRISPR\/Cas off-target sites","volume":"3","author":"Cradick","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1038\/mtna.2016.49_bib43","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1021\/ac202028g","article-title":"High-throughput droplet digital PCR system for absolute quantitation of DNA copy number","volume":"83","author":"Hindson","year":"2011","journal-title":"Anal Chem"}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253117300628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253117300628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:23:33Z","timestamp":1761873813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253117300628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":43,"alternative-id":["S2162253117300628"],"URL":"https:\/\/doi.org\/10.1038\/mtna.2016.49","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726593736.793540455","asserted-by":"object"}]},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CNS-restricted Transduction and CRISPR\/Cas9-mediated Gene Deletion with an Engineered AAV Vector","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/mtna.2016.49","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Official journal of the American Society of Gene & Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"e338"}}